Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever

Critical Care Medicine

Volumn 39, Issue 5, 2011, Pages 993-999

  Lin, Chou Han ^a   Yao, Ming ^b   Hsu, Szu Chun ^b   Ho, Chao Chi ^b   Lin, Ming Tzer ^a   Lin, Chih An ^b   Hu, Fu Chang ^b   Yu, Chong Jen ^b   Tien, Hwei Fang ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

C reactive protein; infection; neutropenic fever; procalcitonin; sepsis; soluble triggering receptor expressed on myeloid cells 1

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN; RITUXIMAB; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ADULT; AGED; BONE MARROW CELL; CHEMOTHERAPY; COMPARATIVE STUDY; CONFERENCE PAPER; DISEASE MARKER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 79955481145     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31820a92dc     Document Type: Conference Paper

References (36)

1. Buchheidt D, Böhme A, Cornely OA, et al: Diagnosis and treatment of documented in-fections in neutropenic patients\Recom-mendations of the Infectious Diseases Work-ing Party (DGHO). Ann Hematol 2003; 82(Suppl 2):S127-S132 (Pubitemid 37265299)
2. Schiel X, Hebart H, Kern WV, et al: Sepsis in neutropenia. Guidelines of the infectious Disease Working Party (AGIHO) of the Ger-man Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82(Suppl 2): S158-S166 (Pubitemid 37265303)
3. Persson L, Engervall P, Magnuson A, et al: Use of inflammatory markers for early detec-tion of bacteremia in patients with febrile neutropenia. Scand J Infect Dis 2004; 36: 365-371 (Pubitemid 38967694)
4. Sakr Y, Sponholz C, Tuche F, et al: The role of procalcitonin in febrile neutropenic pa-tients: Review of the literature. Infection 2009; 36:396-407
5. Pihusch M, Pihusch R, Fraunberger P, et al: Evaluation of C-reactive protein, interleu-kin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 2006; 76:93-101
6. de Bont ES, Vellenga E, Swaanenburg JC, et al: Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neu-tropenia. Br J Haematol 1999; 107:375-380 (Pubitemid 29530226)
7. Schüttrumpf S, Binder L, Hagemann T, et al: Procalcitonin: A useful discriminator be-tween febrile conditions of different origin in hemato-oncological patients? Ann Hematol 2003; 82:98-103 (Pubitemid 36700983)
8. Bouchon A, Dietrich J, Colonna M: Cutting edge: Inflammatory response can be trig-gered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2001; 164:4991-4995 (Pubitemid 30305166)
9. Knapp S, Gibot S, de Vos A, et al: Cutting edge: expression patterns of surface and sol-uble triggering receptor expressed on my-eloid cells-1 in human endotoxemia. J Im-munol 2004; 173:7131-7134 (Pubitemid 39628147)
10. Gibot S, Cravoisy A, Levy B, et al: Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. NEngl J Med 2004; 350:451-458 (Pubitemid 38133765)
11. Gibot S, Kolopp-Sarda MN, Béné MC, et al: Plasma level of a triggering receptor ex-pressed on myeloid cells-1: Its diagnostic ac-curacy in patients with suspected sepsis. Ann Intern Med 2004; 141:9-15
12. Oude Nijhuis C, Kamps WA, Daenen SM, et al: Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 2005; 23:7437-7444 (Pubitemid 46291805)
13. Bouadma L, Luyt CE, Tubach F, et al: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomized controlled trial. Lancet 2010; 375:463-474
14. Ho CC, Liao WY, Wang CY, et al: TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 2008; 177:763-770
15. Ascioglu S, RexJH, de Pauw B, et al: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34:7-14 (Pubitemid 33152659)
16. Chen CY, Chen YC, Tang JL, et al: Hepato-splenic fungal infection in patients with acute leukemia in Taiwan: Incidence, treatment, and prognosis. Ann Hematol 2003; 82:93-97
17. Gorschlüter M, Mey U, Strehl J, et al: Neu-tropenic enterocolitis in adults: Systemic analysis of evidence quality. Eur J Haematol 2005; 75:1-13 (Pubitemid 40873955)
18. Raber-Durlacher JE, Epstein JB, Raber J, et al: Periodontal infection in cancer patients treated with high-dose chemotherapy. Sup-port Care Cancer 2002; 10:466-473 (Pubitemid 36056271)
19. Kelker MS, Foss TR, Peti W, et al: Crystal structure of human triggering receptor ex-pressed on myeloids cells 1 (TREM-1) at 1.47 Å. J Mol Biol 2004; 342:1237-1248 (Pubitemid 39207900)
20. Oberhoffer M, Stonans I, Russwurm S, et al: Procalcitonin expression in human periph-eral blood mononuclear cells and its modu-lation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134:49-55 (Pubitemid 29332170)
21. Maruna P, Nedelnikova K, Gurlich R: Physi-ology and genetics of procalcitonin. Physiol Res 2000; 49:57-61
22. Nijsten MW, Olinga P, The TH, et al: Procal-citonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28:458-461 (Pubitemid 30120889)
23. Bouchon A, Facchetti F, Weigand MA, et al: TREM-1 amplifies inflammation and is a cru-cial mediator of septic shock. Nature 2001; 410:1103-1107 (Pubitemid 32391042)
24. Sharif O, Knapp S: From expression to sig-naling: Roles of TREM-1 and TREM-2 in in-nate immunity and bacterial infection. Im-munobiology 2008; 213:701-713
25. Wiersinga WJ, Veer CT, Wieland CW, et al: Expression profile and function of trigger-ing receptor expressed on myeloid cells-1 during meliodosis. J Infect Dis 2007; 196: 1707-1716 (Pubitemid 351411971)
26. Chen LC, Laskin JD, Gordon MK, et al: Reg-ulation of TREM expression in hepatic mac-rophages and endothelial cells during acute endotoxemia. Exp Mol Pathol 2007; 84: 145-155
27. Gibot S, Le Renard PE, Bollaert PE, et al: Surface triggering receptor expressed on myeloid cells 1 expression patterns in sep-tic shock. Intensive Care Med 2005; 31: 594-597 (Pubitemid 40543894)
28. Gingras MC, Lapillonne H, Margolin JF: TREM-1, MDL-1 and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol 2001; 38: 817-824 (Pubitemid 34260883)
29. Gibot S: Clinical review: Role of triggering receptor expressed on myeloid cells-1 during sepsis. Crit Care 2005; 9:485-489 (Pubitemid 41498545)
30. Crofton RW, Diesselhoff-den Dulk MM, van Furth R: The origin and kinetics and charac-teristics of the Kupffer cells in the normal steady state. J Exp Med 1978; 148:1-17 (Pubitemid 8376473)
31. van Furth R, Diesselhoff-Den Dulk MM, Rae-burn JA, et al: Characteristics, origin and kinetics of human and murine mononuclear phagocytes. In: Mononuclear Phagocytes. Functional Aspects. van Furth R (Ed). The Hague, Martinus Nijhoff, 1980, pp 279-298
32. Van oud Alblas AB, van Furth R: Origin, kinetics and characteristics of pulmonary mac-rophages in the normal steady state. J Exp Med 1979; 149: 1504-1518 (Pubitemid 9209557)
33. Hambach L, Eder M, Dammann E, et al: Diagnostic value of procalcitonin serum lev-els in comparison with C-reactive protein in allogeneic stem cell transplantation. Haema-tologica 2002; 87:643-651 (Pubitemid 34640648)
34. Engel A, Steinbach G, Kern P, et al: Diagnos-tic value of procalcitonin serum levels in neutropenic patients with fever: Comparison with interleukin-8. Scand J Infect Dis 1999; 31:185-189 (Pubitemid 29355529)
35. Gibot S, Kolopp-Sarda MN, Béné MC, et al: A soluble form of the triggering receptor ex-pressed on myeloid cells-1 modulates the in-flammatory response in murine sepsis. J Exp Med 2004; 200:1419-1426 (Pubitemid 39657289)
36. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-751 (Pubitemid 34194843)